Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 79

1.

Circulating DNA as biomarker in breast cancer.

Schwarzenbach H, Pantel K.

Breast Cancer Res. 2015 Oct 9;17(1):136. doi: 10.1186/s13058-015-0645-5.

2.

Data Normalization Strategies for MicroRNA Quantification.

Schwarzenbach H, da Silva AM, Calin G, Pantel K.

Clin Chem. 2015 Nov;61(11):1333-42. doi: 10.1373/clinchem.2015.239459. Epub 2015 Sep 25. Review.

PMID:
26408530
3.

Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients.

Meng X, Joosse SA, Müller V, Trillsch F, Milde-Langosch K, Mahner S, Geffken M, Pantel K, Schwarzenbach H.

Br J Cancer. 2015 Nov 3;113(9):1358-66. doi: 10.1038/bjc.2015.340. Epub 2015 Sep 22.

PMID:
26393886
4.

[Point of care ultrasound: why not?].

Turma J, Schwarzenbach HR.

Praxis (Bern 1994). 2015 Sep 16;104(19):995-6. doi: 10.1024/1661-8157/a002123. German. No abstract available.

PMID:
26373904
5.

The clinical relevance of circulating, exosomal miRNAs as biomarkers for cancer.

Schwarzenbach H.

Expert Rev Mol Diagn. 2015;15(9):1159-69. doi: 10.1586/14737159.2015.1069183. Epub 2015 Jul 22.

PMID:
26202667
6.
7.

The potential of circulating nucleic acids as components of companion diagnostics for predicting and monitoring chemotherapy response.

Schwarzenbach H.

Expert Rev Mol Diagn. 2015 Feb;15(2):267-75. doi: 10.1586/14737159.2015.980817. Epub 2014 Nov 10.

PMID:
25382372
8.

Differential regulation of MAGE-A1 promoter activity by BORIS and Sp1, both interacting with the TATA binding protein.

Schwarzenbach H, Eichelser C, Steinbach B, Tadewaldt J, Pantel K, Lobanenkov V, Loukinov D.

BMC Cancer. 2014 Nov 3;14:796. doi: 10.1186/1471-2407-14-796.

9.

Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients.

Eichelser C, Stückrath I, Müller V, Milde-Langosch K, Wikman H, Pantel K, Schwarzenbach H.

Oncotarget. 2014 Oct 30;5(20):9650-63.

10.

Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.

Müller V, Gade S, Steinbach B, Loibl S, von Minckwitz G, Untch M, Schwedler K, Lübbe K, Schem C, Fasching PA, Mau C, Pantel K, Schwarzenbach H.

Breast Cancer Res Treat. 2014 Aug;147(1):61-8. doi: 10.1007/s10549-014-3079-3. Epub 2014 Aug 3.

PMID:
25086636
11.

Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases.

Joosse SA, Müller V, Steinbach B, Pantel K, Schwarzenbach H.

Br J Cancer. 2014 Aug 26;111(5):909-17. doi: 10.1038/bjc.2014.360. Epub 2014 Jul 1.

12.

Clinical relevance of circulating cell-free microRNAs in cancer.

Schwarzenbach H, Nishida N, Calin GA, Pantel K.

Nat Rev Clin Oncol. 2014 Mar;11(3):145-56. doi: 10.1038/nrclinonc.2014.5. Epub 2014 Feb 4. Review.

PMID:
24492836
13.

Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis.

Ell B, Mercatali L, Ibrahim T, Campbell N, Schwarzenbach H, Pantel K, Amadori D, Kang Y.

Cancer Cell. 2013 Oct 14;24(4):542-56. doi: 10.1016/j.ccr.2013.09.008.

14.

Circulating nucleic acids as biomarkers in breast cancer.

Schwarzenbach H.

Breast Cancer Res. 2013;15(5):211. Review.

15.

Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression.

Eichelser C, Flesch-Janys D, Chang-Claude J, Pantel K, Schwarzenbach H.

Clin Chem. 2013 Oct;59(10):1489-96. doi: 10.1373/clinchem.2013.205161. Epub 2013 Jun 7.

16.
17.

[Jaundice and pathological liver values].

Schwarzenbach HR.

Praxis (Bern 1994). 2013 Jun 5;102(12):727-9. doi: 10.1024/1661-8157/a001333. Review. German.

PMID:
23735764
18.

[ICAN (intensive care medicine, surgery, anesthesia and emergency medicine): a new section of SGUM (Swiss Ultrasound Medicine Society)].

Schwarzenbach HR, Tuma J.

Praxis (Bern 1994). 2013 Jun 5;102(12):701-2. doi: 10.1024/1661-8157/a001320. German. No abstract available.

PMID:
23735759
19.

Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression.

Schwarzenbach H, Eichelser C, Kropidlowski J, Janni W, Rack B, Pantel K.

Clin Cancer Res. 2012 Oct 15;18(20):5719-30. doi: 10.1158/1078-0432.CCR-12-0142. Epub 2012 Sep 25.

20.

[«Knobology» (important device settings)].

Rosenberg I, Schwarzenbach HR, Tuma J.

Praxis (Bern 1994). 2012 Sep 5;101(18):1207-12. doi: 10.1024/1661-8157/a001062. German.

PMID:
22945824
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk